

David J Jackson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3496563/publications.pdf>

Version: 2024-02-01

67
papers

3,782
citations

185998

28
h-index

138251

58
g-index

67
all docs

67
docs citations

67
times ranked

4016
citing authors

#	ARTICLE	IF	CITATIONS
1	IL-33-Dependent Type 2 Inflammation during Rhinovirus-induced Asthma Exacerbations <i>In Vivo</i> . American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1373-1382.	2.5	500
2	The role of viruses in acute exacerbations of asthma. Journal of Allergy and Clinical Immunology, 2010, 125, 1178-1187.	1.5	305
3	Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Science Translational Medicine, 2014, 6, 256ra134.	5.8	280
4	Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nature Medicine, 2017, 23, 681-691.	15.2	260
5	Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness. Journal of Allergy and Clinical Immunology, 2017, 140, 909-920.	1.5	178
6	Characterization of Severe Asthma Worldwide. Chest, 2020, 157, 790-804.	0.4	165
7	Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest, 2021, 159, 496-506.	0.4	159
8	Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. Chest, 2020, 158, 491-500.	0.4	135
9	Eosinophilic and Noneosinophilic Asthma. Chest, 2021, 160, 814-830.	0.4	109
10	Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clinic Proceedings, 2021, 96, 2694-2707.	1.4	103
11	A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN- γ and IFN- λ) and Type 2 Inflammation (IL-5 and IL-13). EBioMedicine, 2017, 19, 128-138.	2.7	102
12	Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respiratory Medicine, 2021, 9, 57-68.	5.2	88
13	Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. Thorax, 2021, 76, 220-227.	2.7	83
14	Pathogenesis of Viral Infection in Exacerbations of Airway Disease. Annals of the American Thoracic Society, 2015, 12, S115-S132.	1.5	76
15	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3997-4004.	2.0	74
16	Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respiratory Medicine, 2022, 10, 47-58.	5.2	74
17	Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies. Annual Review of Immunology, 2021, 39, 719-757.	9.5	69
18	Role of interleukin 33 in respiratory allergy and asthma. Lancet Respiratory Medicine, 2014, 2, 226-237.	5.2	60

#	ARTICLE	IF	CITATIONS
19	Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma. <i>European Respiratory Journal</i> , 2020, 55, 1902259.	3.1	55
20	Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. <i>Advances in Therapy</i> , 2020, 37, 718-729.	1.3	48
21	Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab. <i>Drug Safety</i> , 2020, 43, 409-425.	1.4	47
22	Rhinovirus Infections and Their Roles in Asthma: Etiology and Exacerbations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 673-681.	2.0	46
23	The influence of asthma control on the severity of virus-induced asthma exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 497-500.e3.	1.5	42
24	Potential Severe Asthma Hidden in UK Primary Care. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1612-1623.e9.	2.0	42
25	Disease-modifying anti-asthmatic drugs. <i>Lancet, The</i> , 2022, 399, 1664-1668.	6.3	42
26	M1-like macrophages are potent producers of anti-viral interferons and M1-associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma exacerbations. <i>EBioMedicine</i> , 2020, 54, 102734.	2.7	37
27	The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2093-2096.e1.	2.0	37
28	Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. <i>ERJ Open Research</i> , 2020, 6, 00451-2020.	1.1	33
29	Benralizumab after suboptimal response to mepolizumab in severe eosinophilic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1890-1893.	2.7	33
30	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. <i>Journal of Pragmatic and Observational Research</i> , 2021, Volume 12, 93-104.	1.1	32
31	Eosinophils and eosinophilic immune dysfunction in health and disease. <i>European Respiratory Review</i> , 2022, 31, 210150.	3.0	32
32	Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 422-432.	2.0	28
33	Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>ERJ Open Research</i> , 2020, 6, 00311-2019.	1.1	26
34	Rhinovirus-induced VP1-specific Antibodies are Group-specific and Associated With Severity of Respiratory Symptoms. <i>EBioMedicine</i> , 2015, 2, 64-70.	2.7	24
35	Biologic treatment options for severe asthma. <i>Current Opinion in Immunology</i> , 2020, 66, 151-160.	2.4	23
36	Pulmonary Innate Lymphoid Cell Responses during Rhinovirus-induced Asthma Exacerbations <i>In Vivo</i> : A Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1259-1273.	2.5	22

#	ARTICLE	IF	CITATIONS
37	Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1202-1216.e23.	2.0	22
38	Real-World Effectiveness of Anti-IL-5/5R Therapy in Severe Atopic Eosinophilic Asthma with Fungal Sensitization. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2315-2320.e1.	2.0	21
39	Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1534-1544.e4.	2.0	21
40	Are emerging PGD2 antagonists a promising therapy class for treating asthma?. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 359-364.	1.0	20
41	A pragmatic guide to choosing biologic therapies in severe asthma. <i>Breathe</i> , 2021, 17, 210144.	0.6	20
42	Interleukin-18 Is Associated With Protection Against Rhinovirus-Induced Colds and Asthma Exacerbations. <i>Clinical Infectious Diseases</i> , 2015, 60, 1528-1531.	2.9	19
43	Workup of Severe Asthma. <i>Chest</i> , 2021, 160, 2019-2029.	0.4	18
44	Prescribing Patterns and Treatment Adherence in Patients with Asthma During the COVID-19 Pandemic. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 100-107.e2.	2.0	17
45	Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2238-2241.	2.7	15
46	Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 283-291.	1.5	14
47	The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?. <i>ERJ Open Research</i> , 2021, 7, 00768-2020.	1.1	14
48	Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 344-356.	1.4	13
49	Prevention and Treatment of Asthma Exacerbations in Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2578-2586.	2.0	13
50	Inflammatory and microbiological associations with near-fatal asthma requiring extracorporeal membrane oxygenation. <i>ERJ Open Research</i> , 2020, 6, 00267-2019.	1.1	11
51	Prevalence and recovery of adrenal insufficiency in steroid-dependent asthma patients receiving biologic therapy. <i>European Respiratory Journal</i> , 2020, 56, 1902273.	3.1	10
52	The prevalence of mucus plugging in severe eosinophilic asthma and its relationship to clinical efficacy of anti-IL-5R treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1102-1103.e1.	2.0	8
53	Assessing adherence to inhaled therapies in asthma and the emergence of electronic monitoring devices. <i>European Respiratory Review</i> , 2022, 31, 210271.	3.0	8
54	Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthma. <i>PLoS ONE</i> , 2017, 12, e0183864.	1.1	7

#	ARTICLE	IF	CITATIONS
55	Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma: a pilot randomised controlled trial. <i>Thorax</i> , 2022, 77, 950-959.	2.7	7
56	Improving Care in Eosinophil-Associated Diseases: A Charter. <i>Advances in Therapy</i> , 2022, 39, 2323-2341.	1.3	6
57	Biologics in severe asthma: Which one, When and Where?. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1225-1228.	1.4	5
58	Late Breaking Abstract - Defining a severe asthma super-responder: findings from a Delphi process. , 2020, , .		5
59	COVID-19 in the absence of eosinophils: The outcome of confirmed SARS-CoV-2 infection whilst on treatment with benralizumab. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2558-2560.	2.7	5
60	Recommendations following a modified UK-Delphi consensus study on best practice for referral and management of severe asthma. <i>BMJ Open Respiratory Research</i> , 2021, 8, e001057.	1.2	4
61	Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information. <i>PLoS ONE</i> , 2021, 16, e0258689.	1.1	2
62	Diagnosing adrenal insufficiency using ACTH stimulation test. <i>European Respiratory Journal</i> , 2020, 56, 2002149.	3.1	2
63	Safety of eosinophil depletion. , 2022, , 238-252.		2
64	Eosinophilic asthma. , 2022, , 73-99.		2
65	Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy. <i>European Respiratory Journal</i> , 2021, 57, 2100166.	3.1	1
66	Introducing the Severe Asthma Series of Invited Reviews. <i>Chest</i> , 2021, 160, 1151-1152.	0.4	1
67	Response. <i>Chest</i> , 2020, 158, 2230-2231.	0.4	0